Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Investors might want to bet on Apollo Commerical Finance (ARI) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by th ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Doximity (DOCS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Ind ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Milestone Pharmaceuticals (MIST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

Key Takeaways UNH beat Q4 EPS estimates as Optum Rx strength helped drive a 12% year-over-year revenue increase.UNH saw profits fall as elevated medical costs pushed the medical care ratio sharply higher year over year.UNH forecast 2026 EPS of at least $17.75 with improved margins, while revenue is expected to be below 2025.UnitedHealth Group Incorporated (UNH) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.11, which beat the Zacks Consensus Estimate of $2.09. However, the bottom line ...

核心观点 - 万事达卡预计将于2026年1月29日盘前公布2025年第四季度财报 市场普遍预期每股收益为4.20美元 营收为87.4亿美元[1] 公司拥有强劲的盈利超预期历史 过去四个季度均超出预期 平均超出幅度为3.1%[4] 基于正面的盈利ESP和Zacks排名 模型预测本次财报可能再次超出预期[5] - 尽管公司基本面稳健 长期增长动力持久 但当前估值高于行业及同业 限制了短期上行空间 在四季度财报发布前夕 投资者可能更适合暂时持有并等待更具吸引力的入场时机[21][24] 财务预期与历史表现 - **第四季度预期**：市场对第四季度每股收益的共识预期为4.20美元 较去年同期增长10% 营收共识预期为87.4亿美元 同比增长16.7%[1][2] - **全年预期**：2025年全年营收共识预期为327.3亿美元 同比增长16.2% 每股收益共识预期为16.44美元 同比增长12.6%[3] - **历史表现**：公司在过去四个季度均超出盈利共识预期 平均超出幅度为3.1%[4] 第四季度业绩驱动因素 - **交易量与金额**：总刷卡金额预计同比增长约11% 其中国内业务GDV预计增长8% 欧洲业务GDV预计增长17.1%[8][9] 受消费者支出韧性和公司推广非接触式支付举措推动 交换交易量预计同比增长9.4%[10] - **跨境与评估收入**：受跨境旅行增加推动 跨境评估收入预计同比增长18.1%[11] 国内评估收入和交易处理评估收入预计分别同比增长11.9%和14.3%[11] - **增值服务**：增值服务与解决方案净收入的共识预期为同比增长23.1% 模型估计增幅接近20% 增长由咨询、营销服务和忠诚度解决方案的需求推动[12] - **成本与激励**：调整后运营费用预计同比增长近19% 主要因一般行政成本及广告营销费用上升[14] 支付网络返佣和激励预计同比增长21.6%[14] 估值与股价表现 - **股价表现**：过去三个月 万事达卡股价下跌6.8% 同期Visa下跌5.3% 美国运通上涨0.6% 三者表现均优于行业8.8%的跌幅 同期标普500指数上涨1.4%[15] - **估值水平**：尽管股价下跌 公司估值仍高于行业平均 当前基于未来12个月收益的远期市盈率为27.35倍 高于行业平均的19.43倍 也高于Visa的24.59倍和美国运通的21.56倍[19] 业务基本面与竞争环境 - **业务优势**：交易量持续健康增长 跨境活动随旅行复苏而反弹 增值服务快速扩张 加强了经常性高利润率收入 这些因素巩固了公司的长期增长故事[22] - **面临挑战**：来自英国和美国的监管与法律压力带来了新闻风险 来自灵活金融科技公司和替代支付渠道的竞争持续加剧[23] 更广泛的市场轮动和宏观不确定性可能导致优质金融股估值进一步被压缩[23]

Key Takeaways BDX launched BD Research Cloud 7.0 globally to expand its AI-driven flow cytometry platform.BDX added Horizon Panel Maker, using AI to speed and optimize research panel design.BDX said the platform improves lab workflows, collaboration, and software-driven revenue.Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the global commercial launch of BD Research Cloud 7.0, marking another step forward in its AI-driven life sciences strategy. The latest upgrade strengthe ...